After modification with monomethoxyl-poly(ethylene glycol)-5000, a recombinant intracellular uricase from Bacillus fastidiosus ATCC 29604 showed residual activity of about 65%, a thermo-inactivation half-life >85 h, a circulating half-life about 20 h in rats in vivo, consistent effects of common cations, and consistent optima for reaction temperature and pH. Thus, this uricase can be formulated via modification with monomethoxyl-poly(ethylene glycol).
The elevation of uric acid in human plasma to levels over its solubility leads to hyperuricemia, which is usually associated with hyperxanthinia and deteriorates many pathological processes, including gout, tumor lysis syndrome, kidney dysfunction, and cardiovascular disease. [1] [2] [3] [4] [5] Uricase is established as a protein drug for treatment of hyperuricemia, because it converts uric acid into allantoin, which is highly soluble and has negligible pathophysiological action. [6] [7] [8] [9] [10] An enzyme drug should have both a thermo-inactivation half-life at 37 C and a circulating half-life in vivo as long as possible, catalytic activity in vivo as high as possible, and negligible immunogenicity. The pharmaceutical value of an enzyme protein is often enhanced by modification of its amino groups with monomethoxyl-poly(ethylene glycol) (mPEG). [11] [12] [13] [14] Nevertheless, after modification with mPEG, the activities of most uricases are greatly reduced. [15] [16] [17] [18] [19] To date, the optima of reaction pH for uricases are reported to be over 8.5. At physiological pH, eukaryotic uricases conserve more of their maximum activities, but show low thermostability and high sensitivity to competitive inhibition by xanthine, whose plasma levels are increased in hyperuricemia. [20] [21] [22] [23] [24] Hence, new uricases with high catalytic activity, strong resistance to xanthine, and high thermostability are desired.
Recently, we discovered a new intracellular uricase from Bacillus fastidiosus ATCC 29604 with high catalytic capacity and strong resistance to xanthine, and cloned the main coding domain sequence except for the two N-terminal amino acid residues (GeneBank accession no. FJ393559). 25) However, a commercial uricase (Fluka 94310), from an unknown strain of B. fastidiosus, was inactivated by modification of its amino groups with N-hydroxysuccinimide (NHS) esters of mPEG in the absence of urate or its analogs. 16 ) Fluka 94310 had a Michaelis constant (K m ) of approximately 75 mM, 26) much lower than that of the intracellular uricase from B. fastidiosus ATCC 29604. 25) Hence, there must be some differences among uricases from different strains of B. fastidiosus. To search for possible formulation methods of the intracellular uricase from B. fastidiosus ATCC 29604 as a biodrug, the effects of modification of amino groups of the recombinant uricase with convenient mPEG derivatives were examined.
The intracellular uricase gene was cloned by PCR from the genome of B. fastidiosus ATCC 29604 with an upstream primer of 5 0 -CAGGATGGTAAAGGCGAC-GTATA-3 0 and a downstream primer of 5 0 -GTCAA-CGCCATAGTCGATTTTAAC-3 0 . The resulting PCR product was further amplified using an upstream primer of 5 0 -AATCCATGGCGGAACGCACGATGTTTTAT-GGT-3 0 and a downstream primer of 5 0 -ATACAAG-CTTATTATAGTGCAACATACTCCGAGTTAG-3 0 for subsequent insertion into pET28a following digestion by NcoI and HindIII. After amplification of the desired vector in Escherichia coli DH5, E. coli BL21 (DE3) cells were then transformed with the vector, and positive clones were selected and further amplified. After induction with isopropyl -D-thiogalactoside for 16 h at 18 C, the E. coli cells were lysed by ultrasonic treatment, and the soluble uricase was purified over two consecutive DEAE-cellulose chromatography columns (Whatman, Kent, UK) via elution with 0.1 M Tris-HCl at pH 8.0 plus a linear gradient of NaCl from 0 to 0.4 M. 25, 27) Eluted fractions with activities over 6.0 UÁmg À1 protein were pooled, and were dialyzed against 50 mM sodium borate buffer (Na 2 B 4 O 7 . 10H 2 O) at pH 9.2 for 2 d at 4
C with a change of buffer every 6 h. Contaminating proteins were undetectable in the uricase preparation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The N-terminus deduced from the primers for PCR amplification was MAERTMFYGKGDV. After removal of the first methionine, its molecular weight was calculated to be * These authors contributed equally to this work. Polymers, of mPEG-5000 (mPEG5k) and mPEG-350 (Sigma, St. Louis, MO), were added at 0.6 mmole to succinic anhydride (0.12 g) in 100 ml of tetrahydrofuran (THF) plus 3 ml of pyridine, and this was stirred under a nitrogen atmosphere at 60 C for 24 h. After removal of the THF, each mPEG-succinate intermediate was precipitated and washed repeatedly with ethyl ether. Each intermediate was then dissolved in 50 ml THF, followed by the addition of 0.173 g of NHS and 0.31 g of dicyclohexylcarbodiimide. After reaction under room temperature for 8 h and removal of the precipitates, the NHS ester of each mPEG-succinate in THF was purified by repeated precipitation and washing with ethyl ether.
28) The NHS ester of acetate was prepared similarly. The yield of each NHS ester based on mass weight was over 75%. All the NHS esters were frozen, at below À10 C in sealed bottles until use. An indicated amount of each of the aforementioned NHS esters (powders) was added to the uricase after dialysis against 50 mM sodium borate at pH 9.2, followed by gentle stirring at 4 C for 30 min. 28) Before and after modification, aliquots of the uricase were withdrawn to quantify the amounts of amino groups and uricase activities respectively (potential interference from the NHS ester was corrected by adding the same amount of NHS ester in borate buffer for incubation under the same conditions and for the same duration). Unless otherwise stated, the molar equivalent of the NHS ester of mPEG350 or mPEG5k for modification of the uricase was equal to 200-fold the molar amount of uricase subunits that have the identical molecular weight of 36 kD. For comparison, the modified and unmodified uricases were further dialyzed at 4 C against 50 mM sodium borate buffer at pH 9.2 for 8 h.
27) These preparations of uricase were frozen at below À10 C and thawed slowly at 25 C before characterization. The protein concentrations were quantified by the Bradford method using bovine serum albumin as the standard. 29) Reaction with 2,4,6-trinitrobenzenesulfonic acid (Sigma, St. Louis, MO) was used to quantify amino groups, with glycine as the reference. 30) Unless otherwise stated, either a final concentration of 75.0 mM was used or the indicated levels of uric acid were used in 50 mM sodium borate buffer at pH 9.2 to measure initial rates by monitoring the change in absorbance at 293 nm at (25 AE 0:5) C, and the reaction was initiated by adding 100-ml uricase sample to make up 1.20 ml reaction mixture. [25] [26] [27] [28] One unit of uricase oxidized one micromole uric acid per min.
Each subunit of the recombinant uricase possessed 16 lysine residues (GenBank accession no. FJ393559). Modification of the uricase with a large excess of the NHS ester of acetate concomitantly caused a complete loss of its determinable amino groups and inactivation of the uricase. The NHS esters of mPEG350 and mPEG5k in large excess, however, modified the amino groups, by approximately 85% and 65%, and gave residual uricase activities of about 15% and 65% respectively (Fig. 1) .
It is possible that some amino groups in the uricase were essential for its action but were accessible by the NHS ester of acetate, and hence modification of the uricase with NHS esters of mPEGs of bulk sizes is more desirable for its formulation.
The unmodified uricase had an optimum reaction pH, slightly below 9.2, which was not altered by modification with the NHS ester of mPEG5k or mPEG350. At pH 7.4, the residual activity of the uricases modified with the NHS ester of mPEG5k and of mPEG350 was still about 16% of that at pH 9.2. Because some metal ions, such as iron and calcium, precipitate at pH 9.2 in 50 mM sodium borate buffer, the effects of cations were investigated with 50 mM Tris-HCl buffer at pH 7.4. At a final level of 10 mM, potassium chloride, sodium chloride, and ammonium chloride, slightly To calculate the molar ratios, the molecular weight of the uricase subunit was 36 kD, and the molecular weight of the NHS ester of mPEG350 or mPEG5k was taken to be its average. a, The modification with the NHS ester of acetate. b, The modification with the NHS ester of mPEG350. c, The modification with the NHS ester of mPEG5k. activated individually, whereas magnesium chloride and calcium chloride strongly activated the unmodified uricase. Iron and copper ions inhibited the unmodified uricase activity at 0.2 mM, but exhibited negligible inhibition at 5.0 mM. After modification with the NHS ester of mPEG5k and of mPEG350, the inhibition effects of iron and copper ions, and the activation effects of the other common cations, were slightly weakened at pH 7.4. The effects of iron and copper ions were perhaps related to their interactions with the unique cysteine in each subunit of this uricase (GenBank accession no. FJ393559). The susceptibility of structures of this uricase to ionic strength of solutions might account for the effects of the other common cations. 27) At 25 C, the unmodified uricase had a K m of 0:27 AE 0:03 mM (n ¼ 3) at pH 9.2, and xanthine and oxonate had inhibition constants of 55 AE 12 mM and 8 AE 2 mM respectively (n ¼ 3 for each). Hypoxanthine and adenine showed negligible inhibition at 0.5 mM at pH 9.2. Most eukaryotic uricases have K m values below 30 mM, but the inhibition constants of xanthine on such eukaryotic uricases were nearly 5 mM. 16, 17, 23, 24) After modification of the uricase with the NHS ester of mPEG5k and of mPEG350, its K m and the inhibition constants of these inhibitors exhibited negligible changes. Of either the unmodified or the modified uricase in 50 mM sodium borate buffer at pH 9.2, the K m increased to over 0.80 mM, and the inhibition constant of xanthine increased to over 0.10 mM when the reaction temperature was 40 C. The effects of entropy on the binding of uric acid and xanthine might account for these increases in both K m and the inhibition constants at higher temperatures.
The unmodified uricase showed an optimum reaction temperature below 25 C, which might have been due principally to the increase in K m with the increase in the reaction temperature and the use of a substrate concentration much lower than K m to measure initial rates. After modification of the uricase with the NHS ester of mPEG5k and of mPEG350, the optimum reaction temperature showed no change. At 40 C in sodium borate buffer at pH 9.2, the unmodified uricase showed a thermo-inactivation half-life of about 40 h (Fig. 2a) . Modification of the uricase by the NHS ester of acetate at a molar equivalent equal to 200-fold of the amount of uricase subunits had no effect on its thermostability, while modification by mPEG350 slightly enhanced its thermostability, and modification by mPEG5k increased its thermo-inactivation half-life to over 85 h at 40 C in sodium borate buffer at pH 9.2.
The results described above confirmed that the recombinant uricase from B. fastidiousus ATCC 29604 in the absence of any ligand tolerated modification of its amino groups with the NHS ester of mPEG of a reasonable size. Therefore, the effect of modification of the uricase with NHS esters of mPEG on its circulating half-life in vivo was examined in preliminary fashion. After modification with the NHS ester of mPEG5k, the native uricase left-over was about 20% of the total protein in the preparation as analyzed by SDS-PAGE. Preparations of the modified and the unmodified uricase were filtered through a 0.22 mm membrane before injection into male rats via the caudal vein (body weight 230 AE 10 g, n ¼ 5 for each group). From the moment 5 min after the injection of 0.5 U uricase, approximately 0.5 ml of blood was taken from the orbital vein at indicated times and centrifuged at 3;000 Â g for 10 min at 4 C to obtain plasma which was kept at 4 C until the assay of uricase activity in 2 h. The circulating half-life of the unmodified uricase was approximately 20 min. Sixty min after injection of the unmodified uricase, its activities in plasma reached the detection limit (Fig. 2b) . The circulating half-life of the uricase after modification with the NHS ester of mPEG350 was approximately 1.5 h (data not shown). To approximate the circulating half-life of the uricase that was fully modified with the NHS ester of mPEG5k, uricase activities in plasma were analyzed from that 60 min after injection of the uricase preparation to alleviate interference from the unmodified uricase (Fig. 2b) . The resulting circulating half-life of the fully modified uricase was 20 AE 10 h (n ¼ 5).
These results confirmed that modification of the recombinant uricase from B. fastidiousus ATCC 29604 with an NHS ester of mPEG of an optimum size is a plausible option for its formulation as a protein drug. The problem of the unfavorable optimum reaction temperature can be effectively alleviated in vivo in hyperuricemic patients due to much higher concentrations of plasma uric acid. At 40 C, the recombinant a b Fig. 2 . Stability of the Recombinant Uricase. a, Thermo-stability at 40 C in vitro in 50 mM sodium borate buffer at pH 9.2. Uricase activities in different systems were the same at the starting points, and final results were amplified or reduced to facilitate discrimination of the plots. b, Stability in vivo in the plasma of healthy rats.
uricase from Aspergillus flavus has a thermo-inactivation half-life of about 2.0 h, 20) and the recombinant uricase from Candida utilis (GenBank accession no. GU476487) showed a thermo-inactivation half-life of within 2.0 h (data not shown). The recombinant uricase of B. fastidiousus ATCC 29604 displayed favorable thermostability and a prolonged circulating half-life in vivo after modification with mPEG5k, and its modification with an NHS ester of mPEG of an optimum size is expected to enhance its thermostability and to further prolong its circulating half-life in vivo. [17] [18] [19] Therefore, after modification with an NHS ester of mPEG of an optimum size, the recombinant uricase from B. fastidiousus ATCC 29604 shows promise to be an enzyme drug for hyperuricemia.
